HD Clinical Trials, HD Community

GENERATION HD2-Clinical Trial Open to the Huntington’s Disease Community

The HDSA RESEARCH WEBINAR: The Roche/Genentech GENERATION HD2 Study of Tominersen; a new clinical trial that is now open to folks with Huntington’s disease (HD) who meet the criteria. The webinar is worth watching.  
Tominersen is an antisense therapy that acts by reducing the production of all forms of the huntingtin protein (HTT), including its mutated variant (mHTT), which is believed to be the main cause of HD.

Info on the study:
-Adults 25-50 years of age (early stage of HD)
-360 people in the study
-Clinical trial locations will be in 15 countries; more than 1 in US
-16 month treatment period
Go to: http://gene.com/patients/clinical-trial-information to read about the Tominersen study and how to get involved. Or ClinicalTrials.gov or signup for HDTrialFinder

Huntington’s disease is a rare, fatal, genetic brain disorder that has NO CURE, strikes young, is a long and progressive disease and has the symptoms of ALS, Alzheimer’s and Parkinson’s, simultaneously.  41,000 Americans are symptomatic and approximately 200,000 are at risk.

We Can Never Lose Hope…

I’m a Huntington’s disease (HD) advocate, Chair for the HDSA San Francisco Bay Area Affiliate, a blogger and author.  Visit my website  https://theresecrutchermarin.com

Previous Post Next Post

You Might Also Like

No Comments

Leave a Reply